Neuropharmacological effects of calycosin: a translational review of molecular mechanisms and therapeutic applications
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-10 · 398 (10) · 12891-12909
DOI: 10.1007/s00210-025-04154-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 16.04.2025. Verfasst von H Shafeeq Ahmed. Beteiligte Einrichtung: Bangalore Medical College and Research Institute, K.R Road, Bangalore, 560002, Karnataka, India. shafeeqahmed2002@gmail.com. Hauptthemen laut MEDLINE: Isoflavones, Neuroprotective Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 122 Literaturangaben.
Abstract (Originalsprache)
Calycosin, a naturally occurring isoflavonoid found predominantly in Astragalus membranaceus, exhibits significant therapeutic potential in various neurological conditions. Its multifaceted bioactive properties-antioxidant, anti-inflammatory, and anti-apoptotic-position it as a promising candidate for neuroprotection and neuroregeneration. This review explores calycosin's mechanisms of action, including its modulation of key signaling pathways such as HMGB1/TLR4/NF-κB (high mobility group box 1/toll-like receptor 4/nuclear factor kappa B), phosphatidylinositol-3-kinase (PI3 K)/Akt, ERK1/2 (extracellular signal-regulated kinase 1/2), and Hsp90/Akt/p38. In cerebral ischemia/reperfusion injury, calycosin reduces oxidative stress markers like ROS (reactive oxygen species) and MDA (malondialdehyde), enhances antioxidant enzymes (SOD (superoxide dismutase) and GPX (glutathione peroxidase)), and downregulates pro-inflammatory cytokines (TNF-α, IL-1β) through the HMGB1/TLR4/NF-κB pathway. It also inhibits autophagy via the STAT3/FOXO3a pathway and apoptosis by modulating Bax and Bcl-2 expression. In neuro-oncology, calycosin inhibits glioblastoma cell migration and invasion by modulating the TGF-β-mediated mesenchymal properties and suppressing the c-Met and CXCL10 signaling pathways. Additionally, it enhances the efficacy of temozolomide in glioma treatment through apoptotic pathways involving caspase-3 and caspase-9. Calycosin shows promise in Alzheimer's disease by reducing β-amyloid production and tau hyperphosphorylation via the GSK-3β pathway and improving mitochondrial function through the peroxisome proliferator-activated receptor gamma coactivator 1-Alpha (PGC-1α)/mitochondrial transcription factor A (TFAM) signaling pathway. In Parkinson's disease, calycosin mitigates oxidative stress, prevents dopaminergic neuronal death, and reduces neuroinflammation by inhibiting the TLR/NF-κB and MAPK pathways. It has also shown therapeutic potential in meningitis and even neuroprotective effects against hyperbilirubinemia-induced nerve injury. Despite these promising findings, further research, including detailed mechanistic studies and clinical trials, is needed to fully understand calycosin's therapeutic mechanisms and validate its potential in human subjects. Developing advanced delivery systems and exploring synergistic therapeutic strategies could further enhance its clinical application and effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bangalore Medical College and Research Institute, K.R Road, Bangalore, 560002, Karnataka, India. shafeeqahmed2002@gmail.com.
Zitieren
APA
Ahmed, H. S. (2025). Neuropharmacological effects of calycosin: a translational review of molecular mechanisms and therapeutic applications. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(10), 12891-12909. https://doi.org/10.1007/s00210-025-04154-3
Vancouver
Ahmed HS. Neuropharmacological effects of calycosin: a translational review of molecular mechanisms and therapeutic applications. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(10):12891-12909. doi:10.1007/s00210-025-04154-3
BibTeX
@article{Ahmed2025,
author = {Ahmed, H Shafeeq},
title = {Neuropharmacological effects of calycosin: a translational review of molecular mechanisms and therapeutic applications},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {10},
pages = {12891--12909},
doi = {10.1007/s00210-025-04154-3}
}
EUVIMED